세계의 먹는 백신(Edible Vaccine) 시장 : 유형별, 용도별, 지역별(2026-2032년)

Edible Vaccine Market Valuation - 2026-2032

The rising demand for alternative vaccination methods, particularly in developing regions, is propelling interest in edible vaccines as they offer an easier, needle-free delivery mechanism that enhances accessibility and compliance. Increasing prevalence of infectious diseases and growing focus on preventive healthcare are encouraging research investments and innovation in this field. The need for edible vaccine is surpassing USD 8.35 Billion in 2023 and reaching USD 12.91 Billion by 2032.

Additionally, advances in plant biotechnology, which enable the genetic modification of crops to produce vaccines, have strengthened the feasibility of edible vaccines. The cost-effectiveness, ease of storage, and transport of edible vaccines further fuel market expansion as these factors address critical challenges in global immunization efforts. These factors contribute to the increasing use of edible vaccine in a variety of industries is expected to grow at a CAGR of 6.18% about from 2026 to 2032.

Edible Vaccine Market: Definition/ Overview

Edible vaccines are genetically engineered crops or plants that produce antigens, stimulating an immune response when consumed, offering a needle-free, easily administered vaccination method. Their primary applications include combating infectious diseases like hepatitis B, cholera, and rabies, where traditional vaccination faces logistical or accessibility barriers. Looking ahead, edible vaccines hold potential for widespread, cost-effective immunization, especially in low-resource settings, as they reduce cold-chain dependency and production costs. Advances in plant biotechnology and growing interest in preventive health are expected to drive future developments, making edible vaccines a promising tool for global public health initiatives.

Will Growing Awareness of Preventive Healthcare is Propelling the Edible Vaccine Market?

Growing awareness of preventive healthcare is significantly propelling the Edible Vaccine Market. As populations become increasingly conscious of preventive health, there is a shift towards proactive measures in combating diseases, boosting interest in innovative vaccination solutions like edible vaccines. The World Health Organization (WHO) notes that vaccine-preventable diseases cause approximately 1.5 million deaths each year, emphasizing the need for effective immunization strategies. In the United States, the Centers for Disease Control and Prevention (CDC) reports a rising trend in vaccination awareness, with vaccination coverage among children reaching nearly 95% for diseases like polio and measles, showcasing the population's inclination toward preventive healthcare.

This demand for accessible, non-invasive vaccine solutions, particularly in regions with limited healthcare infrastructure, aligns with the benefits of edible vaccines, further fueling the market. Additionally, edible vaccines offer solutions to critical logistical challenges in vaccination. Unlike traditional vaccines, they don't require refrigeration, making them especially suitable for areas without consistent cold-chain infrastructure. According to a United Nations report, over 30% of low-income countries face cold chain shortages, which impact effective immunization coverage. Edible vaccines can help address these challenges, as they can be produced and distributed locally with fewer resources.

Will High Costs and Accessibility Hamper the Growth of the Edible Vaccine Market?

High costs and accessibility challenges could hamper the growth of the Edible Vaccine Market. Developing edible vaccines requires advanced genetic engineering, rigorous clinical trials, and regulatory approvals, all of which add to production costs. These expenses may limit affordability, especially in low- and middle-income countries where traditional vaccines are often subsidized by government programs or international organizations. This high-cost structure could slow adoption rates, particularly in regions where funding is limited.

Moreover, accessibility remains a concern as infrastructure for large-scale cultivation and distribution of genetically engineered crops may not be available everywhere. Strict regulatory frameworks governing genetically modified organisms (GMOs) in regions like Europe also present obstacles, potentially restricting edible vaccine deployment. As a result, while edible vaccines offer promising benefits, high costs and accessibility limitations pose significant challenges to their widespread adoption.

Category-Wise Acumens

Will Widespread Usage for Inactivated Vaccine Boost the Edible Vaccine Market?

The widespread usage of inactivated vaccines can indirectly boost the Edible Vaccine Market. Inactivated vaccines are well-regarded for their safety and effectiveness, fostering trust in vaccine-based preventive healthcare. This acceptance creates a favorable environment for innovative vaccines like edible vaccines, as the public becomes more open to varied vaccination methods. As awareness of different vaccine types grows, so does the interest in more accessible, needle-free alternatives, which could drive adoption of edible vaccines, especially in communities with high demand for convenient immunization options.

Furthermore, as inactivated vaccines require careful storage and distribution, edible vaccines offer an appealing alternative in areas where cold-chain logistics are challenging. Since edible vaccines can be produced in plants, they eliminate the need for cold storage and complex distribution, addressing critical barriers associated with inactivated vaccines in low-resource settings. This added advantage could position edible vaccines as a complementary solution, further enhancing the market's growth potential.

The "Others" segment, which includes newer vaccine technologies like mRNA and viral vector vaccines, is the fastest-growing.

Will Comprehensive Ability to Provide Medical Care Fuel the Edible Vaccine Market?

The comprehensive ability of edible vaccines to enhance medical care can fuel market growth. Edible vaccines offer a promising, needle-free alternative to traditional vaccines, making immunization more accessible, especially in regions with limited healthcare infrastructure. This ability to simplify vaccine administration aligns with public health goals for increased vaccination coverage, particularly in areas where medical resources and trained personnel are scarce.

Additionally, edible vaccines reduce logistical challenges associated with cold-chain storage and distribution. As they can be produced and stored with minimal refrigeration needs, edible vaccines lower costs and improve reach in remote and underserved areas. This ease of distribution and storage supports broader healthcare initiatives, making edible vaccines an attractive option to expand medical care capabilities globally, further driving their market potential.

The Livestock segment is the fastest-growing, fueled by increasing demand for efficient, cost-effective solutions to manage animal diseases in agriculture.

Country/Region-wise

Will Advanced Healthcare Infrastructure in North America Drive the Expansion of The Edible Vaccine Market?

The advanced healthcare infrastructure in North America is likely to drive the expansion of the Edible Vaccine Market. With highly developed research facilities, the region is well-positioned to support innovation in vaccine delivery systems like edible vaccines, addressing the need for easier, needle-free alternatives. The United States, in particular, invests significantly in healthcare, with federal research funding for the National Institutes of Health (NIH) reaching approximately $47.5 billion in 2022, part of which supports vaccine research and development. This robust investment landscape accelerates breakthroughs in biotechnology, supporting edible vaccine advancements.

Furthermore, high vaccination rates and supportive regulatory frameworks in North America create a favorable environment for introducing novel vaccine types. For example, in 2022, the U.S. Centers for Disease Control and Prevention (CDC) reported that approximately 72% of the population had received full COVID-19 vaccinations, showing widespread vaccine adoption and an openness to innovative health solutions. As demand for effective, accessible, and affordable vaccination options grows, edible vaccines are positioned to benefit from the region's sophisticated healthcare infrastructure and regulatory support, potentially leading to their expanded use in public health initiatives.

Will Rapid Economic Growth in Asia Pacific Propel the Edible Vaccine Market?

Rapid economic growth in the Asia-Pacific region is likely to propel the Edible Vaccine Market, primarily due to increased investment in healthcare infrastructure and a heightened focus on preventive health measures. As nations such as China and India continue to experience robust economic expansion, the demand for innovative healthcare solutions, including edible vaccines, is expected to rise significantly. According to the Asian Development Bank, the region's economy is projected to grow by approximately 5.5% in 2024, which will likely lead to increased government spending on health initiatives and improved access to vaccination programs.

Furthermore, the Asia-Pacific region faces a high burden of infectious diseases, which underscores the need for accessible vaccination solutions. The World Health Organization reported that vaccine-preventable diseases caused over 1.5 million deaths annually in low- and middle-income countries, many of which are located in this region. As governments aim to enhance immunization coverage, edible vaccines offer a viable alternative to traditional methods, facilitating easier distribution and administration. The combination of economic growth and an urgent health mandate creates a favorable environment for the Edible Vaccine Market to thrive in the Asia-Pacific region.

Competitive Landscape

The competitive landscape of the Edible Vaccine Market is characterized by rapid technological advancements and increasing innovation in diagnostic tools. Companies are focusing on developing more accurate, non-invasive, and user-friendly testing solutions to meet the growing demand for personalized and preventive healthcare. Strategic collaborations, mergers, and acquisitions are also common as firms aim to enhance their market presence and expand their product offerings.

Some of the prominent players operating in the Edible Vaccine Market include:

GlaxoSmithKline, Sanofi S.A., Merck & Co., Inc., Ceva, Santa Cruz Animal Health, Merial.

Latest Developments

In August 2024 A research team at the University of California developed an innovative oral vaccine using genetically modified edible plants. This new approach allows for easy administration without needles, potentially increasing vaccination rates. Early studies showed promising immune responses in animal models, indicating that this method could revolutionize how vaccines are delivered, particularly in underserved regions.

In July 2024 Syngenta announced a partnership with BioNTech to explore the development of edible vaccines using genetically engineered crops. This collaboration aims to leverage BioNTech's mRNA technology to create plants that can produce antigens for various diseases. The initiative could significantly reduce production costs and facilitate wider distribution of vaccines in developing countries.

In June 2024 the Food and Drug Administration (FDA) approved the first edible vaccine for rotavirus, developed by a biotechnology firm in collaboration with agricultural scientists. This landmark decision paves the way for future approvals of edible vaccines, highlighting a growing acceptance of plant-based vaccine technology. The vaccine is expected to be available in various food products, making it more accessible, especially for children in low-income countries.

Edible Vaccine Market, By Category

• Type:
• Inactivated Vaccines
• Others
• Application:
• Livestock
• Medical Care
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL EDIBLE VACCINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL EDIBLE VACCINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL EDIBLE VACCINE MARKET, BY APPLICATION

• 5.1 Overview
• 5.2 Livestock
• 5.3 Medical Care

6 GLOBAL EDIBLE VACCINE MARKET, BY TYPE

• 6.1 Overview
• 6.2 Inactivated Vaccines
• 6.3 Others

7 GLOBAL EDIBLE VACCINE MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East & Africa

8 GLOBAL EDIBLE VACCINE MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 GlaxoSmithKline
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Sanofi S.A.
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Merck & Co., Inc.
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Ceva
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Santa Cruz Animal Health
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Merial
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments

10 KEY DEVELOPMENTS

• 10.1 Product Launches/Developments
• 10.2 Mergers and Acquisitions
• 10.3 Business Expansions
• 10.4 Partnerships and Collaborations

11 Appendix

• 11.1 Related Research